ATE378407T1 - Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen - Google Patents

Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen

Info

Publication number
ATE378407T1
ATE378407T1 AT95918920T AT95918920T ATE378407T1 AT E378407 T1 ATE378407 T1 AT E378407T1 AT 95918920 T AT95918920 T AT 95918920T AT 95918920 T AT95918920 T AT 95918920T AT E378407 T1 ATE378407 T1 AT E378407T1
Authority
AT
Austria
Prior art keywords
morphogen
methods
cell surface
surface receptors
identifying
Prior art date
Application number
AT95918920T
Other languages
English (en)
Inventor
Peter Dijke
Kohei Miyazano
Kuber Sampath
Carl-Henrik Heldin
Original Assignee
Curis Inc
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Ludwig Inst Cancer Res filed Critical Curis Inc
Application granted granted Critical
Publication of ATE378407T1 publication Critical patent/ATE378407T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AT95918920T 1994-04-29 1995-04-28 Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen ATE378407T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23642894A 1994-04-29 1994-04-29

Publications (1)

Publication Number Publication Date
ATE378407T1 true ATE378407T1 (de) 2007-11-15

Family

ID=22889467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918920T ATE378407T1 (de) 1994-04-29 1995-04-28 Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen

Country Status (8)

Country Link
US (4) US5863738A (de)
EP (1) EP0756628B1 (de)
JP (1) JPH10511840A (de)
AT (1) ATE378407T1 (de)
AU (1) AU702163B2 (de)
CA (1) CA2187902A1 (de)
DE (1) DE69535641D1 (de)
WO (1) WO1995030003A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE234920T1 (de) * 1992-11-17 2003-04-15 Ludwig Inst Cancer Res Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
AU709991B2 (en) * 1995-08-14 1999-09-09 Creative Biomolecules, Inc. Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof
US20040002117A1 (en) * 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
DK1131087T4 (da) † 1998-11-13 2009-08-03 Stryker Corp Lindring af prostatacancersymptomer
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
BRPI9915679B8 (pt) 1998-11-27 2021-05-25 Darwin Discovery Ltd composições e métodos para aumentar a mineralização óssea
DE60033576T2 (de) * 2000-11-06 2007-10-31 Thrasos, Inc., Waltham Methoden zum screening knochenmorphogenetishemimetika
CA2431035A1 (en) * 2000-11-06 2002-05-10 Thrasos, Inc. Computer method and apparatus for classifying objects
WO2003055443A2 (en) * 2001-10-31 2003-07-10 Alcon, Inc. Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
RS20050934A (en) 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
EP2789342A1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Verbindungen im Zusammenhang mit TDF und Analoga davon
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
HUE040063T2 (hu) * 2005-07-19 2019-02-28 Stemgen S P A Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
CA2863125A1 (en) 2005-09-20 2007-03-29 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CA2631013C (en) * 2005-11-23 2019-06-11 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US8859752B2 (en) 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
WO2013106175A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
EP2140005B1 (de) * 2007-03-19 2013-12-11 National Research Council of Canada Fusionsproteine, die zwei tgf-beta bindende domänen enthalten
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SG171813A1 (en) 2008-11-26 2011-07-28 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
DK3195880T3 (da) 2010-05-14 2020-03-02 Amgen Inc Højkoncentrerede anti-sclerostin-antistofformuleringer
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
MA35009B1 (fr) 2011-03-25 2014-04-03 Amgen Inc Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
JP6363954B2 (ja) 2011-12-28 2018-07-25 アムジエン・インコーポレーテツド 抗スクレロスチン抗体の使用による歯槽骨消失の治療方法
EP3626267A1 (de) 2012-07-05 2020-03-25 UCB Pharma, S.A. Behandlung von knochenerkrankungen
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2951205B1 (de) 2013-02-01 2021-08-11 Santa Maria Biotherapeutics, Inc. Anti-aktivin-a-verbindungen zur behandlung vom ovarialkrebs
FR3024462A1 (fr) * 2014-07-29 2016-02-05 Univ Pierre Et Marie Curie Paris 6 Procede de production in vitro de progeniteurs adipocytaires et d'adipocytes
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
SG11202008206TA (en) 2018-03-30 2020-09-29 Amgen Inc C-terminal antibody variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011366A1 (en) * 1989-03-28 1990-10-04 Genetics Institute, Inc. Osteoinductive compositions
GB8827367D0 (en) 1988-11-23 1988-12-29 Lawrence C A Spinning of yarn
DE69032424T2 (de) * 1989-10-17 1999-02-04 Stryker Corp., Kalamazoo, Mich. Osteogene vorrichtungen
ATE197611T1 (de) * 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
DE4225427A1 (de) * 1992-07-31 1994-02-03 Boehringer Mannheim Gmbh Verfahren zur Gewinnung rekombinanter, biologisch aktiver, eukaryontischer alkalischer Phosphatase
ATE234920T1 (de) * 1992-11-17 2003-04-15 Ludwig Inst Cancer Res Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor

Also Published As

Publication number Publication date
EP0756628B1 (de) 2007-11-14
US5863738A (en) 1999-01-26
CA2187902A1 (en) 1995-11-09
JPH10511840A (ja) 1998-11-17
DE69535641D1 (de) 2007-12-27
AU2466295A (en) 1995-11-29
AU702163B2 (en) 1999-02-18
EP0756628A1 (de) 1997-02-05
WO1995030003A2 (en) 1995-11-09
US20050233379A1 (en) 2005-10-20
US6632618B1 (en) 2003-10-14
WO1995030003A3 (en) 1995-12-14
US20020155500A1 (en) 2002-10-24
US7067260B2 (en) 2006-06-27

Similar Documents

Publication Publication Date Title
ATE378407T1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
NZ500253A (en) Osteoprotegerin binding proteins and receptors
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
NO995458D0 (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
DE69838254D1 (de) Zwei menschliche g-protein-gekoppelte rezeptorproteine: ebv-induzierter gpcr2 (ebi-2) und egd-1-ähnlicher gpcr
DK1012274T3 (da) Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
WO1997007135A3 (en) Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
ATE226216T1 (de) Netrinrezeptoren
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
ATE323764T1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
EP1005539A4 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
EP0833948A4 (de) Für den dickdarm spezifische gene und proteine
SE9602822D0 (sv) New receptor
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
EP0846763A3 (de) R5, ein Protein Phosphatase-1 bindendes Protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties